Vijaya Diagnostic Centre has strengthened its board governance by appointing Mr. Satyanaryana Murthy Chavali and Mr. Dipinder Singh Sekhon as Non-Executive Independent Directors. The appointments, effective May 26, 2026, are for terms of five and two years respectively and are subject to shareholder approval. The decision was taken via a circular resolution by the Board of Directors.

Director Profiles and Tenures

The new directors bring extensive experience in pharmaceuticals and technology to the Vijaya Diagnostic Centre board. Mr. Chavali has been appointed for a five-year term, while Mr. Sekhon will serve for two years. Both appointments comply with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Background and Expertise

Mr. Satyanaryana Murthy Chavali holds a Bachelor of Technology from the Indian Institute of Technology Madras and a Post Graduate Diploma in Management from the Indian Institute of Management Bangalore. He previously served as the Chief Executive Officer of Aurigene Discovery Technologies Limited and held senior leadership roles at Dr. Reddy's Laboratories Limited. His expertise spans pharmaceutical research, drug discovery, and corporate governance.

Mr. Dipinder Singh Sekhon is a technology entrepreneur and AI strategist with over two decades of experience in artificial intelligence and medical imaging. He is the Founder of iKITES.ai and Ophthal.ai. An alumnus of the Indian Institute of Technology Delhi, he has co-founded KritiKal Solutions and is associated with the Foundation for Innovation and Technology Transfer (FITT).

Regulatory Disclosures

The company confirmed that neither appointee is related to any existing director on the Board. Furthermore, both individuals are not debarred from holding the office of director pursuant to any SEBI order or any other authority. The detailed disclosures were made in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

vijaya diagnostic centre witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 207,713 shares changing hands in a single transaction. The deal was executed at a price of ₹1345.50 per share, aggregating to a total transaction value of ₹27.95 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades of this scale are typically executed by institutional investors or large stakeholders and are carried out outside the regular order book to minimise market impact. The transaction in Vijaya Diagnostic Centre reflects significant interest from large-scale market participants in the company's stock.